DDInter1431 DDInter902
Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Perindopril may be used to treat mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.
Icatibant is a synthetic decapeptide with 5 nonproteinogenic amino acid antagonist targeting the B<sub>2</sub> receptors with a similar affinity to bradykinin. It is resistant to bradykinin-cleaving enzyme degradation and has a potency of 2-3 times higher than earlier B<sub>2</sub> receptors antagonists, thus representing a new class of medication.[A4017,A263041] It was investigated as a potential treatment of hereditary angioedema (HAE) as bradykinin was implicated in HAE swelling; specifically, mice lacking B<sub>2</sub> receptors showed reduced swelling, thus demonstrating bradykinin involvement in the disease pathophysiology.[A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema.[L49776,L49781] The FDA approval was based on positive results obtained from 3 double-blind, randomized, controlled clinical trials known as FAST 1, 2, and 3, where a median time to almost complete symptom relief was observed to be 8 hours compared to 36 hours for the placebo treatment.
Perindopril {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Icatibant
Perindopril {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Goserelin
Goserelin {u} (Compound) resembles {v} (Compound) Icatibant
Perindopril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alogliptin
Alogliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Goserelin
Goserelin {u} (Compound) resembles {v} (Compound) Icatibant
Perindopril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alogliptin
Alogliptin {u} (Compound) causes {v} (Side Effect) Anaphylactic shock
Anaphylactic shock {u} (Side Effect) is caused by {v} (Compound) Icatibant
Perindopril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Goserelin
Goserelin {u} (Compound) resembles {v} (Compound) Icatibant
Perindopril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glimepiride
Glimepiride {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Icatibant
Perindopril {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium hydroxide
Magnesium hydroxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Goserelin
Goserelin {u} (Compound) resembles {v} (Compound) Icatibant
Perindopril {u} (Compound) binds {v} (Gene) ACE
ACE {u} (Gene) interacts with {v} (Gene) BDKRB2
BDKRB2 {u} (Gene) is bound by {v} (Compound) Icatibant
Perindopril {u} (Compound) treats {v} (Disease) coronary artery disease
coronary artery disease {u} (Disease) is associated with {v} (Gene) BDKRB2
BDKRB2 {u} (Gene) is bound by {v} (Compound) Icatibant
Perindopril {u} (Compound) upregulates {v} (Gene) SATB1
SATB1 {u} (Gene) is regulated by {v} (Gene) BDKRB2
BDKRB2 {u} (Gene) is bound by {v} (Compound) Icatibant
Perindopril (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Icatibant (Compound)
Perindopril (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Goserelin (Compound) and Goserelin (Compound) resembles Icatibant (Compound)
Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Icatibant (Compound)
Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Icatibant (Compound)
Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Icatibant (Compound)
Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Icatibant (Compound)
Perindopril may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Icatibant (Compound)
Perindopril (Compound) binds ACE (Gene) and ACE (Gene) interacts with BDKRB2 (Gene) and BDKRB2 (Gene) is bound by Icatibant (Compound)
Perindopril (Compound) treats coronary artery disease (Disease) and coronary artery disease (Disease) is associated with BDKRB2 (Gene) and BDKRB2 (Gene) is bound by Icatibant (Compound)
Perindopril (Compound) upregulates SATB1 (Gene) and SATB1 (Gene) is regulated by BDKRB2 (Gene) and BDKRB2 (Gene) is bound by Icatibant (Compound)